Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
July 13, 2023
From Benzinga
Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate
June 28, 2023
From Benzinga
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
June 16, 2023
From Benzinga
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
June 14, 2023
From Benzinga
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
June 09, 2023
From Benzinga
AI: An Endless Opportunity or Existential Threat?
June 04, 2023
From InvestorPlace
Why Shares of Zentalis Pharmaceuticals Dropped This Week
June 02, 2023
From Motley Fool
Why Shares of Rain Oncology Are Plummeting Today
May 22, 2023
From Motley Fool
From Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
May 17, 2023
From Benzinga
From InvestorPlace
3 Stocks That Are Reshaping the Future
May 16, 2023
From InvestorPlace
From InvestorPlace
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
May 04, 2023
From Benzinga
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish
April 28, 2023
From Benzinga
From Benzinga
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
April 26, 2023
From Benzinga
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
From Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
April 25, 2023
From Benzinga
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma
April 20, 2023
From Benzinga
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
April 13, 2023
From Benzinga
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
From Motley Fool
From Benzinga
From Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
March 20, 2023
From Benzinga
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
March 17, 2023
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.